Sanofi SA at Citi Immuno-Oncology Summit (Virtual) Transcript
Good morning to those of you in the U.S. Good afternoon to those in Europe, and good evening to those of you in Asia. I'm Peter Verdult and on behalf of Citi's Global Healthcare team delighted to introduce our next speaker Giovanni Abbadessa. He heads up Oncology Early Development at Sanofi and is the global project head for SAR'245 the non-alpha IL-2 program.
As I always say on these events, I'm here to moderate the next sort of 55 minutes rather than monopolize. It's not an open line forum, but there is a chat room functionality on your webinar. So I'll be keeping an eye out if you have any questions you want me to put through to Giovanni, just use that functionality.
Now one thing I'll just address straight away as I'm sure many of you have questions on upcoming and (inaudible) data, but this is not the forum for those questions. And I think the only update from Sanofi is what we said previously that we're expecting the data in Q1. So with all those formalities done and without further ado, Giovanni, maybe over to you. I know you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
